Hillstream BioPharma, Inc.
HILS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $4 | $2 | $2 |
| G&A Expenses | $6 | $6 | $5 | $1 |
| SG&A Expenses | $6 | $6 | $5 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $9 | $7 | $3 |
| Operating Income | -$12 | -$9 | -$7 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$2 | $1 |
| Pre-Tax Income | -$12 | -$9 | -$8 | -$2 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$12 | -$9 | -$8 | -$3 |
| % Margin | – | – | – | – |
| EPS | -9.41 | -7.14 | -0.75 | -0.3 |
| % Growth | -31.8% | -852% | -150% | – |
| EPS Diluted | -9.41 | -7.14 | -0.75 | -0.3 |
| Weighted Avg Shares Out | 1 | 1 | 11 | 10 |
| Weighted Avg Shares Out Dil | 1 | 1 | 11 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | -$0 | $2 | $1 |
| Depreciation & Amortization | $0 | $0 | $1,569 | $2 |
| EBITDA | -$12 | -$9 | -$7 | $0 |
| % Margin | – | – | – | – |